Financial Expectations for 2025
All line items are according to GAAP, except as otherwise noted.
| In millions | 2025 Expectations | |
| Total Revenues | $1,340 – $1,430 | |
| VIVITROL Net Sales | $440 – $460 | |
| ARISTADAi Net Sales | $335 – $355 | |
| LYBALVI Net Sales | $320 – $340 | |
| Cost of Goods Sold | $185 – $205 | |
| R&D Expenses | $305 – $335 | |
| SG&A Expenses | $655 – $685 | |
| GAAP Net Income a | $175 – $205 | |
| EBITDA | $215 – $245 | |
| Adjusted EBITDA | $310 – $340 | |
| Effective Tax Rate | ~17% |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.